Harrow, Inc. Files 8-K Report
Ticker: HROW · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: HROW
TL;DR
Harrow Inc. filed an 8-K on Sept 9, 2024, with financial updates.
AI Summary
On September 9, 2024, Harrow, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Harrow Health, Inc., Imprimis Pharmaceuticals, Inc., and Transdel Pharmaceuticals Inc., is based in Nashville, TN, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides important updates and financial information for Harrow, Inc., which is crucial for investors and stakeholders to understand the company's current status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains factual information and does not inherently signal significant new risks.
Key Players & Entities
- HARROW, INC. (company) — Registrant
- September 9, 2024 (date) — Date of earliest event reported
- Harrow Health, Inc. (company) — Former company name
- Imprimis Pharmaceuticals, Inc. (company) — Former company name
- Transdel Pharmaceuticals Inc (company) — Former company name
- Nashville, TN (location) — Company business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is HARROW, INC.
On what date was this report filed or deemed filed?
The report was filed as of September 9, 2024.
What are some of the former names of Harrow, Inc.?
Harrow, Inc. was formerly known as Harrow Health, Inc., Imprimis Pharmaceuticals, Inc., and Transdel Pharmaceuticals Inc.
What is Harrow, Inc.'s Standard Industrial Classification code and description?
Harrow, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-09-09 07:30:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 502KB
- ex99-1_002.jpg (GRAPHIC) — 517KB
- ex99-1_003.jpg (GRAPHIC) — 266KB
- ex99-1_004.jpg (GRAPHIC) — 254KB
- ex99-1_005.jpg (GRAPHIC) — 161KB
- ex99-1_006.jpg (GRAPHIC) — 200KB
- ex99-1_007.jpg (GRAPHIC) — 179KB
- ex99-1_008.jpg (GRAPHIC) — 274KB
- ex99-1_009.jpg (GRAPHIC) — 212KB
- ex99-1_010.jpg (GRAPHIC) — 171KB
- ex99-1_011.jpg (GRAPHIC) — 235KB
- ex99-1_012.jpg (GRAPHIC) — 321KB
- ex99-1_013.jpg (GRAPHIC) — 299KB
- ex99-1_014.jpg (GRAPHIC) — 173KB
- 0001493152-24-035390.txt ( ) — 5491KB
- hrow-20240909.xsd (EX-101.SCH) — 4KB
- hrow-20240909_def.xml (EX-101.DEF) — 31KB
- hrow-20240909_lab.xml (EX-101.LAB) — 37KB
- hrow-20240909_pre.xml (EX-101.PRE) — 28KB
- form8-k_htm.xml (XML) — 8KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: September 9, 2024 By: /s/ Andrew R. Boll Name: Andrew R. Boll Title: Chief Financial Officer